Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
FT-522 by Fate Therapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
FT-522 is under clinical development by Fate Therapeutics and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to...
FT-522 by Fate Therapeutics for Follicular Lymphoma: Likelihood of Approval
FT-522 is under clinical development by Fate Therapeutics and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...
FT-522 by Fate Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
FT-522 is under clinical development by Fate Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...
FT-522 by Fate Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
FT-522 is under clinical development by Fate Therapeutics and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...